NCT04784897View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

July 30, 2021

Conditions
COVID-19
Interventions
DRUG

Brilacidin

Brilacidin IV infusion

DRUG

Placebo

Placebo IV infusion

DRUG

Standard of Care (SoC)

SoC therapies for COVID-19

Trial Locations (12)

43608

IPI Investigator Site, Toledo

60190

IPI Investigator Site, Winfield

111398

IPI Investigator Site, Moscow

119048

IPI Investigator Site, Moscow

121359

IPI Investigator Site, Moscow

125367

IPI Investigator Site, Moscow

196600

IPI Investigator Site, Pushkin

198205

IPI Investigator Site, Saint Petersburg

198510

IPI Investigator Site, Saint Petersburg

199106

IPI Investigator Site, Saint Petersburg

603155

IPI Investigator Site, Nizniy Novgorod

656045

IPI Investigator Site, Barnaul

Sponsors
All Listed Sponsors
lead

Innovation Pharmaceuticals, Inc.

INDUSTRY